You just read:

Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers

News provided by

Oncolytics Biotech Inc.

Nov 21, 2013, 06:00 ET